Home › Immune System and Disorders › Oregon
Immune System and Disorders clinical trials in Oregon
9 studies for Immune System and Disorders are looking for participants at sites in Oregon.
Cities in Oregon
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
- Oregon Health & Science University, Portland
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07192471A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Oregon Health & Science University, Portland
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT06722235Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
- Saint Alphonsus Cancer Care Center-Baker City, Baker City
- Saint Charles Health System, Bend
- Clackamas Radiation Oncology Center, Clackamas
- and 9 more
RecruitingObservational study
All ages · All sexes · Updated Sep 17, 2026 · NCT04242095A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Oregon Health & Science University, Portland
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT06948318A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
- Providence Portland Medical Center, Portland
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT07075185A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
- Inmagene Site 3, Portland
RecruitingPhase 2
Ages 18 to 74 · All sexes · Updated Aug 12, 2026 · NCT07037901Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Oregon Health and Science University, Portland
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 7, 2026 · NCT07216443CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- Providence Neurological Specialties West, Portland
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Apr 16, 2026 · NCT03328078A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
- Oregon Health and Science University, Portland
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Dec 15, 2025 · NCT06619561From ClinicalTrials.gov, data retrieved Oct 4, 2026. Each study sets its own eligibility; the study team decides who can join.